NCT06492876View on ClinicalTrials.gov

Gene Therapy for DME

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2028

Conditions
Diabetic Macular Edema
Interventions
GENETIC

FT-003

Administered via intraocular injection.

Trial Locations (1)

300392

RECRUITING

Tianjin Medical University Eye Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Frontera Therapeutics

INDUSTRY

NCT06492876 - Gene Therapy for DME | Biotech Hunter | Biotech Hunter